Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains...
According to Spherix Global Insights, nephrologists and rheumatologists express measured optimism about these treatment options and seek more experience with...
Managed care decisions will likely have a substantial impact on shaping rheumatologists’ future IL-17 preference, according to Spherix Global Insights...
According to Spherix Global Insights, specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology have little interest in engaging with industry,...
According to Spherix Global Insight’s COVID-19 tracker, dermatologists and rheumatologists alike report that they are more inclined to use Otezla...
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis)...
Lupus has high unmet needs and a very active pipeline, including AstraZeneca’s anifrolumab, Eli Lilly’s Olumiant, novel TYK-2 inhibitors from...
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains...
The firm, which was recently recognized by Philadelphia Business Journal as one of the area’s Soaring 76 fastest growing companies...
According to Spherix Global Insights, just one-tenth of specialty physician offices are operating at normal capacity, and doctors report facing...
Spherix Global Insights releases fifth annual patient chart study focused exclusively on biologic and small molecule switching patterns among US...
A stark contrast in use and preference of the JAK inhibitors between the two regions sets varying competitive landscapes for...
